Dr. Oaknin on the Safety Profile of Dostarlimab in Endometrial Cancer
Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the safety profile of dostarlimab (TSR-042) in patients with endometrial cancer.
Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the safety profile of dostarlimab (TSR-042) in patients with endometrial cancer.
Dostarlimab is well tolerated among patients, says Oaknin. However, in 70% of patients enrolled in the phase I/II GARNET trial, investigators did observe treatment-related adverse events (AEs). In terms of immune-related AEs, less than 6% of patients developed grade 3 or 4 events. Additionally, no deaths were reported as a result of the drug, she adds.
Regarding the agent’s mechanism of action, dostarlimab is an investigational, humanized antibody that prevents the interaction between PD-1 and PD-L1. Moreover, it stimulates the immune system to fight a patient’s tumor cells and has shown a strong signal of activity in patients with recurrent or advanced microsatellite instability—high and microsatellite stable endometrial cancer.
